ASPIRE: Driving Better Outcomes

November 9, 2022

Table of Contents

Text Link

Go Back

Driving Better Outcomes

Wellinks is excited to announce the final results of ASPIRE – a clinical trial conducted with the COPD Foundation to assess the impact of Wellinks on quality of life, engagement and satisfaction among COPDF members living with COPD.

Circle with 3 images- laptop, smartphone and call screenshot - Wellinks Images

Each participant received personalized health coaching, virtual pulmonary rehabilitation, and monitoring through connected devices and a patient-facing app.
‍
The study enrolled 141 members in the trial, with 119 completing the 24-week study. These results demonstrate sustained engagement, satisfaction, and clinical response with Wellinks.

Interested in learning more about Wellinks?

Request a Demo Today

Wellinks Engagement at 24 Weeks
‍(n = 141)

61%

Finger pressing the "Join" button - Wellinks Images

Enrollment Rate

Proportion successfully enrolled out of all who were interested and eligible

84%

Retention Rate

Proportion who remained enrolled in the study at 24 weeks

These results were demonstrated in a population with...

High Member Satisfaction at 24 Weeks

Over 81% said Wellinks helped them better manage their COPD
Over 92% found Wellinks to be valuable
Over 83% said Wellinks helped them learn more about their COPD

+64

Net Promoter Score*

* Net Promoter Score (NPS) is a customer loyalty and satisfaction measurement taken from asking customers how likely they are to recommend your product. NPS scores range from -100 to +100. This NPS is based on responses from those who continued contact with coaches, representative of the Wellinks clinical model.

Improved Clinical Outcomes at 24 Weeks

Wellinks demonstrated sustained improvements in COPD self-efficacy as measured by the COPD Self-efficacy Scale (CSES) at 24 weeks.

Self-efficacy is a measure of how confident an individual is in managing their COPD and addressing shortness of breath.

One-third of participants demonstrated improvements in Modified Medical Research Council dyspnea score. mMRC is a measure of breathlessness that is associated with risk of future exacerbations.

Sign up to stay updated on ASPIRE and Wellinks.

Thank you! Stay tuned for more Wellinks news soon.

Oops! Something went wrong while submitting the form.

*By providing your email address, you agree to opt into receiving our Wellinks marketing emails.
You can unsubscribe at any time. Your information will be held confidential.